** Drug developer Annovis Bio's ANVS.N shares fall 4.6% to $5.40 premarket
** ANVS files for up to $50 mln "at-the-market" stock sale agreement to be handled by Oppenheimer
** Co plans to use the proceeds for general corporate purposes, including the development of its lead experimental drug buntanetap
** ANVS set to host its year-end investor webcast late Wednesday
** ANVS has 13.8 mln outstanding shares and $78 mln market capitalization - LSEG data
** As of last close, ANVS shares down 69.7% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。